Mind Medicine (MindMed) Inc
NASDAQ:MNMD
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.43
11.75
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MNMD stock under the Base Case scenario is 3.05 USD. Compared to the current market price of 5.57 USD, Mind Medicine (MindMed) Inc is Overvalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Mind Medicine (MindMed) Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MNMD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Mind Medicine (MindMed) Inc
Balance Sheet Decomposition
Mind Medicine (MindMed) Inc
Current Assets | 247.7m |
Cash & Short-Term Investments | 243.1m |
Other Current Assets | 4.6m |
Non-Current Assets | 20.5m |
Intangibles | 19.9m |
Other Non-Current Assets | 534k |
Current Liabilities | 41.8m |
Accounts Payable | 2.9m |
Accrued Liabilities | 8.2m |
Other Current Liabilities | 30.7m |
Non-Current Liabilities | 24.3m |
Long-Term Debt | 24.3m |
Earnings Waterfall
Mind Medicine (MindMed) Inc
Revenue
|
0
USD
|
Operating Expenses
|
-90.5m
USD
|
Operating Income
|
-90.5m
USD
|
Other Expenses
|
-11.6m
USD
|
Net Income
|
-102m
USD
|
Free Cash Flow Analysis
Mind Medicine (MindMed) Inc
USD | |
Free Cash Flow | USD |
MindMed shared significant updates in their Q2 2024 earnings call. They announced the initiation of Phase III trials for MM120 in treating GAD and MDD, leveraging robust Phase II data showing a 48% remission rate at 12 weeks. Financially, they've strengthened their position with $243.1 million in cash, sufficient to fund operations to 2027. R&D expenses are expected to increase as they advance Phase III studies. A successful $75 million public offering also supports their strategy. These milestones aim to position MM120 as a best-in-class treatment in brain health disorders, targeting large market opportunities.
What is Earnings Call?
MNMD Profitability Score
Profitability Due Diligence
Mind Medicine (MindMed) Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Mind Medicine (MindMed) Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
MNMD Solvency Score
Solvency Due Diligence
Mind Medicine (MindMed) Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Mind Medicine (MindMed) Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MNMD Price Targets Summary
Mind Medicine (MindMed) Inc
According to Wall Street analysts, the average 1-year price target for MNMD is 26.78 USD with a low forecast of 14.14 USD and a high forecast of 57.75 USD.
Dividends
Current shareholder yield for MNMD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MNMD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.
Contact
IPO
Employees
Officers
The intrinsic value of one MNMD stock under the Base Case scenario is 3.05 USD.
Compared to the current market price of 5.57 USD, Mind Medicine (MindMed) Inc is Overvalued by 45%.